<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210316050725N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-05-28</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of the metformin in preventing of the preeclampsia</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of metformin in prevention  from severe preeclampsia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/55106</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: After determining the total volume of the sample.papers  A and B are placed in the lottery container. Then the papers are randomly removed from the container without replacement and the created sequence is recorded, Blinding description: The person receiving the medication, the person giving the medication, and the person analyzing the results are unaware of the type of medication 
(metformin or placebo) used.
Placebo (paper A) and metformin tablets (paper B) are poured in equal numbers in a bag. and at the time of the patient's visit who are eligible for the study, she is said to have picked up one of the papers. pills  then given to the patient based on the patient's choice (blind) . (the resident who gives the pill does not know which group of placebo and which group is metformin due to the same packaging. she is blind .). The analyzer also reports the final results under groups A and B (without knowing the type of group).</study_design>
      <phase>3</phase>
      <hc_freetext>Non severe preeclampsia.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group,   pregnant woman with only high blood pressure is given 1000 mg of metformin during her entire pregnancy, and during the course of labor, the symptoms of severe preeclampsia and fetal growth are evaluated. Intervention 2: In the control group, pregnant woman with only high blood pressure is given a placebo for the entire pregnancy and the symptoms of severe preeclampsia and fetal growth are assessed during labor.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
paper

When:
one months after paper print

To whom:
all people

Conditions:
Email

Where to obtain:
Demandants can contact by  Dr. Shahnaz Ahmadi, the principal investigator, or the education office of Akbrabadi Hospital via the email ahmadishahnaz2005 @ yahoo.com and call 02155633244

How to obtain:
respose one month after email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shahnaz Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Molavi street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1168743514</zip>
        <telephone>+98 21 5563 3244</telephone>
        <email>Ahamdishahnaz2005@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahnaz Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Molavi Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1168743514</zip>
        <telephone>+98 21 5563 3244</telephone>
        <email>Ahmadishahnaz2005@yahoocom</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Non severe preeclampsia
Single pregnancy</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Eclamsia
Severe reeclamsia
Renal failure
Insulin -treated diabet</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O14.00</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Mild to moderate pre-eclampsia, unspecified trimester</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group,   pregnant woman with only high blood pressure is given 1000 mg of metformin during her entire pregnancy, and during the course of labor, the symptoms of severe preeclampsia and fetal growth are evaluated</i_keyword>
      <i_keyword>In the control group, pregnant woman with only high blood pressure is given a placebo for the entire pregnancy and the symptoms of severe preeclampsia and fetal growth are assessed during labor.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severe preeclampsia. Timepoint: Weekly untill term pregnancy. Method of measurement: Weekly visit , blood pressure assesment , laboratory assesment.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hypertension. Timepoint: Weekly visit. Method of measurement: with the help of mercury manometer.</sec_outcome>
      <sec_outcome>Fetal growth. Timepoint: Weekly. Method of measurement: Ultrasound.</sec_outcome>
      <sec_outcome>Elevated in liver enzyme. Timepoint: Weekly. Method of measurement: Laboratory.</sec_outcome>
      <sec_outcome>Headache, blurred vision , pain in epigaster. Timepoint: weekly. Method of measurement: Biography.</sec_outcome>
      <sec_outcome>Blood creatinine in mother. Timepoint: Weekly. Method of measurement: Laboratory.</sec_outcome>
      <sec_outcome>Diabet in mother. Timepoint: Monthly. Method of measurement: Assesment of Fast blood sugar and 2 hours after meal.</sec_outcome>
      <sec_outcome>Fetal health assessment tests. Timepoint: Weekly. Method of measurement: Non stress test and biophysical profile.</sec_outcome>
      <sec_outcome>Proteinurea. Timepoint: Weekly. Method of measurement: By collecting urine 24 hours a day.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-28</approval_date>
        <contact_name>Ethics committee of Iran university of medical science</contact_name>
        <contact_address>Molavi Street Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
